From LBR-101 to Fremanezumab for Migraine

@article{Bigal2018FromLT,
  title={From LBR-101 to Fremanezumab for Migraine},
  author={M. Bigal and A. Rapoport and S. Silberstein and S. Walter and R. Hargreaves and Ernesto Aycardi},
  journal={CNS Drugs},
  year={2018},
  volume={32},
  pages={1025-1037}
}
  • M. Bigal, A. Rapoport, +3 authors Ernesto Aycardi
  • Published 2018
  • Medicine
  • CNS Drugs
  • Calcitonin gene-related peptide (CGRP) is a neuropeptide of importance in migraine pathogenesis. Its central role in migraine was proven pharmacologically by the development of CGRP receptor antagonists. Monoclonal antibodies targeting CGRP or its receptor are effective in the preventive treatment of episodic and chronic migraine and are considered potential breakthroughs in their treatment. Fremanezumab (previously known as TEV-48125, LBR-101, or RN-307) is a humanized IgG2a monoclonal… CONTINUE READING
    9 Citations

    Figures, Tables, and Topics from this paper

    Explore Further: Topics Discussed in This Paper

    Fremanezumab as a preventive treatment for episodic and chronic migraine
    • 8
    An Evidence-Based Review of Fremanezumab for the Treatment of Migraine
    • 8
    • PDF
    Fremanezumab in the treatment of migraines: evidence to date
    • 2
    • PDF
    Population pharmacokinetic modelling and simulation of fremanezumab in healthy subjects and patients with migraine
    • 5

    References

    SHOWING 1-10 OF 69 REFERENCES
    TEV-48125: a Review of a Monoclonal CGRP Antibody in Development for the Preventive Treatment of Migraine
    • 34
    Monoclonal Antibodies for Migraine: Preventing Calcitonin Gene-Related Peptide Activity
    • 52
    Calcitonin Gene-Related Peptide-Targeted Therapies for Migraine and Cluster Headache: A Review
    • 27
    Calcitonin gene-related peptide: an update on the biology
    • 71
    Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine.
    • 975
    • PDF
    Blocking CGRP in migraine patients – a review of pros and cons
    • 100
    • PDF
    Therapeutic antibodies against CGRP or its receptor.
    • 73
    Selective Inhibition of Trigeminovascular Neurons by Fremanezumab: A Humanized Monoclonal Anti-CGRP Antibody
    • 69
    • PDF
    Calcitonin Gene‐Related Peptide (CGRP) and Migraine Current Understanding and State of Development
    • 109